Publications by authors named "Tisiana Low"
Objective: To evaluate practice variation in pharmacologic management in the International Kawasaki Disease Registry (IKDR).
Study Design: Practice variation in intravenous immunoglobulin (IVIG) therapy, anti-inflammatory agents, statins, beta-blockers, antiplatelet therapy, and anticoagulation was described.
Results: We included 1627 patients from 30 IKDR centers with maximum coronary artery aneurysm (CAA) z scores 2.
The etiology of Kawasaki Disease (KD), the most common cause of acquired heart disease in children in developed countries, remains elusive, but could be multifactorial in nature as suggested by the numerous environmental and infectious exposures that have previously been linked to its epidemiology. There is still a lack of a comprehensive model describing these complex associations. We present a Bayesian disease model that provides insight in the spatiotemporal distribution of KD in Canada from 2004 to 2017.
View Article and Find Full Text PDFArticle Synopsis
- - The 2017 AHA guidelines for Kawasaki disease (KD) classify long-term management risk levels based on coronary artery dimensions, focusing on current vs. past practices to identify gaps in knowledge translation efforts.
- - Analysis of the International KD Registry showed that the use of recommended treatments like low-dose aspirin and anticoagulation varied significantly among patients classified by their coronary artery risk levels.
- - Overall, past treatment practices generally aligned with AHA guidelines, but there remains a need for improved understanding and consistency in managing thromboprophylaxis.
Background Coronary artery aneurysms (CAAs) may occur after Kawasaki disease (KD) and lead to important morbidity and mortality. As CAA in patients with KD are rare and heterogeneous lesions, prognostication and risk stratification are difficult. We sought to derive the cumulative risk and associated factors for cardiovascular complications in patients with CAAs after KD.
View Article and Find Full Text PDFBackground: Kawasaki disease (KD) may lead to coronary artery aneurysms (CAA) with potential for thrombosis. We aimed to determine the bleeding risk during thromboprophylaxis regimens with dual and triple therapy.
Methods: KD patients with medium to large CAAs receiving combination thromboprophylaxis therapy (dual or triple therapy with acetylsalicylic acid (ASA), clopidogrel, low molecular weight heparin (LMWH) or warfarin) were reviewed (1979-2017).
Background: The substantial risk of thrombosis in large coronary artery aneurysms (CAAs) (maximum z-score ≥ 10) after Kawasaki disease (KD) mandates effective thromboprophylaxis. We sought to determine the effectiveness of anticoagulation (low-molecular-weight heparin [LMWH] or warfarin) for thromboprophylaxis in large CAAs.
Methods: Data from 383 patients enrolled in the International KD Registry (IKDR) were used.